Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New tool helps families with Alzheimer's plan ahead for medical decisions

NCT ID NCT05143255

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to create a communication tool to help people with Alzheimer's or dementia and their caregivers discuss and plan for future medical care. Researchers worked with 38 participants to see if the tool improved their readiness to make advance care plans. The goal was to reduce stress and ensure patients' wishes are respected at the end of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

38 people

The number who actually took part.

Started

Dec 2024

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Below we outline criteria for patient/care recipient (CR) (which includes patient/CR only or patient/CR enrolled as part of a dyad), care partner (CR) (which includes CR only or CR enrolled as part of a dyad), and dyad only relevant eligibility criteria: Patient/care recipient (CR) eligibility criteria: 1. Montreal Cognitive Assessment-Blind (MoCA-B) score of 9-18; 2. decision-making capacity to consent to a low risk study as indicated by a score of ≥9 on the University of California-San Diego Brief Assessment of Capacity to Consent, a 10-item measure validated in patients with challenges in memory; 3. capacity to execute a Health Care Proxy, as indicated by a score of ≥ 11 on the validated and reliable HCP Guidelines for ability to execute a HCP among nursing home residents; 4. age ≥ 65; 5. reports receiving care and/or support from an unpaid care partner; and 6. reports that at least one of their ADs has not been completed (for CR's enrolled without a CP only). A MoCA-B score of 9-18 is consistent with clinical guidelines for an average MoCA score for individuals with mild Alzheimer's disease and is within the threshold for having capacity to complete advance directives. Patients with this score are mobile, communicative, and generally involved in making medical care decisions. While patients must report having a care partner to be eligible, the patient can be enrolled in the study even if their care partner is not enrolled. Care partner (CP) eligibility criteria: 1. provides informal (unpaid) care for a person with memory challenges, per self-report; 2. MoCA-B score of ≥19; and reports that at least one of the CR's ADs has not been completed (for CPs enrolled without a patient only). While care partners must report caring for a person with memory challenges, the care partner can be enrolled in the study even if the patient is not enrolled. Eligibility criteria for CRs and CPs enrolled as a dyad: In addition to the criteria above for CR and CP: (1) the CR and/or CP report that at least one of the CR's ADs has not been completed. Patient and care partner exclusion criteria: 1. not fluent in English; 2. ≤17 years of age; 3. too ill or weak to complete the interviews (per the interviewer); 4. presence of significant sensory, language, or motor deficit (e.g., visual or hearing loss, paralysis, aphasia) (per self report, the interviewer or medical record); or 5. patient is in the late stage of dementia (i.e., severe cognitive impairment), is bed-bound, or has a nursing home admission planned within 12 months per CP report or the medical record.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Weill Cornell Medicine

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.